Skip to main content
Premium Trial:

Request an Annual Quote

Metagenomi Raises $175M in Series B Financing Round

NEW YORK – Gene editing company Metagenomi said on Tuesday that it has raised $175 million in a Series B financing round, bringing the total funding for the Emeryville, California-based startup to $300 million.

The round, which was upsized and oversubscribed, was led by PFM Health Sciences, Farallon Capital Management, and an undisclosed global investment firm. Other new investors included Eventide Asset Management, Deep Track Capital, Frazier Life Sciences, Pura Vida Investments, Irving Investors, Millennium Management, Surveyor Capital, Marshall Wace, Novo Holdings, Bristol Myers Squibb, and strategic partner Moderna. They were joined by existing investors, including RA Capital Management, Leaps by Bayer, and Humboldt Fund.

Launched by scientists at the University of California, Berkeley in 2018, Metagenomi has been screening genomes from microorganisms around the world to identify novel gene editing systems that are capable of precisely editing genomes via single-base changes, knockouts, or integrations, and with lower potential for off-target effects.

The firm plans to use the new funding to further develop these tools and to advance its in vivo and ex vivo gene editing therapeutic programs through preclinical development and into the clinic by expanding its manufacturing, automation, and AI infrastructure.

"We look forward to the next phase of the company's development as we accelerate our lead gene editing programs, and open new treatment options in metabolic, cardiovascular, and CNS diseases, as well as in immuno-oncology," said Brian Thomas, CEO and cofounder of Metagenomi, in a statement.

The new financing follows a $65 million Series A round that Metagenomi completed in November 2020.

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.